Osteoporosis

Results showed treatment with dipeptidyl peptidase-4 inhibitors (DPP-4i) improved bone mineral density and reduced osteoporosis risk in patients with type 2 diabetes.

Patients identified areas of confusion in data presentation and suggested educational support to better engage with the information provided.

A prospective, nonrandomized trial has returned results indicating adolescents and young adults who undergo bariatric surgery experienced a decrease in bone density relative to their counterparts who opted for exercise and nutrition counseling.

An analysis of data from more than 60,000 postmenopausal women within the Women's Health Initiative has returned results indicating the guideline-recommended FRAX score may be insufficient for making screening decisions.

A phase 3 trial comparing QL1206, a denosumab biosimilar, to the reference agent has returned results demonstrating the efficacy, safety, and pharmacokinetic equivalency of the biosimilar to the reference agent.

Most associate bariatric surgery with improved health outcomes, but a new study suggests clinicians and patients should be aware of potential changes in bone density brought on as a result of undergoing bariatric surgery.

The guidelines were created using a panel of rheumatologists, orthopedic surgeons, and patients.

Investigators identify a strong association between exposure to air pollution and bone mineral loss in postmenopausal women.

Each 1-SD increment in HDL-C level was associated with a 14% higher risk of fractures in cohort study of approximately 16,000 community-dwelling healthy adults.

Results of the PREVENT CLOT study indicate use of aspirin was as effective as low-molecular-weight heparin for reducing incidence of mortality in patients hospitalized with a traumatic fracture.

A systematic review and meta-analysis of observational studies of people with diabetes suggest more than 1-in-4 also had a diagnosis of osteoporosis.

Released on January 3, the American College of Physician's living osteoporosis guideline represents the organization's first update on the topic since 2017 and includes 6 specific recommendations for pharmacologic management of osteoporosis or low bone mass.

Announced by Radius Health on December 20, the US FDA approval for abaloparatide (Tymlos) indicates the agent as a treatment to increase bone density in men with osteoporosis at high risk of fracture or in patients who have failed or are intolerant to other available osteoporosis therapy.

An analysis of data from the Cancer Prevention Study-II suggests cancer survivors had a more than doubling in risk of frailty-related bone fractures than their counterparts without cancer.

A study presented at ASBMR 2022 leveraging data from more than a dozen countries details trends in hip fracture incidence and projects potential incidence increases by 2050.

An ancillary study of the landmark VITAL trial provides clinicians with evidence related to the lack of reduction in fracture risk observed with vitamin D3 supplementation in older adults.

An analysis of real-world data from more than 6500 patients suggests insulin users had a greater risk of fracture than patients using metformin, but this became attenuated among patients using a combination of insulin and metformin.

Data from Sweden national registers provide insight into the increased risk of adverse outcomes, including fracture, cardiovascular events, and mortality risk, associated with primary hyperparathyroidism as well as the apparent reductions in risk achieved by undergoing parathyroidectomy.

Analysis of data from more than 75k patients with diabetes in Canada suggests use of SGLT2 inhibitors was not associated with an increased fracture risk compared with DPP-4 inhibitors among patients with diabetic kidney disease.

A secondary analysis of the HIPFRA trial indicates participation in a home-based exercise program was associated with increased functional ability and physical performance in adult patients recovering from hip fracture.

An analysis of data from a Cleveland Clinic database indicates calcium supplementation in older adults with aortic stenosis was linked to an increased risk of mortality and worsening aortic stenosis.

Our endocrine month in review spotlights the most popular articles from the past month. This month's top articles include a multipart video series, new diabetes, information on osteoporosis, and more!

On April 20, the UK National Osteoporosis Guideline Group released updated guidance for the diagnosis, prevention, and treatment of osteoporosis, which has received endorsements from the IOF and ESCEO.

An analysis of data from a 5000-patient cohort suggests use of NSAIDs was associated with a detrimental effect on the benefit of clodronate on reducing risk of fracture among older women.

Using data from NHANES, researchers at the University of Chicago provide insight into associations of fat mass index and lean mass index on bone mineral density and how sex influences these associations.

An analysis of data from more than 50k patients using risedronate or alendronate from Ontario compares the risk of hip fracture and other outcomes during drug holidays.

November's endocrine month in review features stories on the Build Back Better Act, a recent review from the IOF, data from Kidney Week 2021, and more.

The latest review from the International Osteoporosis Foundation is a 14-page document with more than 100 references outlining current data related to the pathophysiological links between vascular calcification and bone loss.

October's endocrine month in review features stories on the new ADA and EASD type 1 diabetes guidance, a phase 2 trial examining oral PTH tablets for osteoporosis, and a 3-part panel discussion focusing on diabetes management in 2021.